R
Rosemary E. Gale
Researcher at University College London
Publications - 108
Citations - 10520
Rosemary E. Gale is an academic researcher from University College London. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 44, co-authored 105 publications receiving 9390 citations. Previous affiliations of Rosemary E. Gale include Ninewells Hospital.
Papers
More filters
Journal ArticleDOI
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
Panagiotis D. Kottaridis,Rosemary E. Gale,Marion E. Frew,G Harrison,Stephen E. Langabeer,Andrea A. Belton,Helen Walker,Keith Wheatley,David T. Bowen,Alan Kenneth Burnett,Anthony H. Goldstone,David C. Linch +11 more
TL;DR: In this article, the impact of internal tandem duplication (ITD) in the FLT3 gene on clinical outcome was evaluated in 854 patients, mostly 60 years of age or younger, treated in the United Kingdom Medical Research Council (MRC) trials.
Journal ArticleDOI
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
Steven J. Howe,Marc R. Mansour,Kerstin Schwarzwaelder,Cynthia C. Bartholomae,Mike Hubank,Helena Kempski,Martijn H. Brugman,Karin Pike-Overzet,S Chatters,Dick de Ridder,Dick de Ridder,Kimberly Gilmour,Stuart Adams,Susannah I. Thornhill,Kathryn L. Parsley,Frank J. T. Staal,Rosemary E. Gale,David C. Linch,Jinhua Bayford,Lucie Brown,Michelle Quaye,Christine Kinnon,Philip Ancliff,David Webb,Manfred Schmidt,Christof von Kalle,H. Bobby Gaspar,Adrian J. Thrasher +27 more
TL;DR: The occurrence of clonal T cell acute lymphoblastic leukemia (T-ALL) promoted by insertional mutagenesis in a completed gene therapy trial of 10 SCID-X1 patients is described and a general toxicity of endogenous gammaretroviral enhancer elements is highlighted.
Journal ArticleDOI
Acute myeloid leukaemia.
Asim Khwaja,Magnus Björkholm,Rosemary E. Gale,Ross L. Levine,Craig T. Jordan,Gerhard Ehninger,Clara D. Bloomfield,Eli Estey,Alan Kenneth Burnett,Jan J. Cornelissen,David A. Scheinberg,Didier Bouscary,David C. Linch +12 more
TL;DR: A plethora of new agents — including those targeted at specific biochemical pathways and immunotherapeutic approaches — are now in trial based on improved understanding of disease pathophysiology, providing good grounds for optimism, although mortality remains high especially in older patients.
Journal ArticleDOI
Assessment of Minimal Residual Disease in Standard-Risk AML.
Adam Ivey,Robert Kerrin Hills,Michael A. Simpson,Jelena V. Jovanovic,Amanda F. Gilkes,Angela Grech,Yashma Patel,Neesa Bhudia,Hassan Farah,Joanne Mason,Kerry Wall,Susanna Akiki,Mike Griffiths,Ellen Solomon,Frank McCaughan,David C. Linch,Rosemary E. Gale,Paresh Vyas,Sylvie D. Freeman,Nigel H. Russell,Alan Kenneth Burnett,David Grimwade +21 more
TL;DR: Although mutations associated with preleukemic clones remained detectable during ongoing remission after chemotherapy, NPM1 mutations were detected in 69 of 70 patients at the time of relapse and provided a better marker of disease status.
Journal ArticleDOI
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
M Fernanda Amary,Stephen Damato,Dina Halai,Malihe Eskandarpour,Fitim Berisha,Fiona Bonar,Stan McCarthy,Valeria Fantin,Kimberly Straley,Samira B Lobo,Will Aston,Claire Green,Rosemary E. Gale,Roberto Tirabosco,Andrew Futreal,Peter J. Campbell,Nadege Presneau,Adrienne M. Flanagan,Adrienne M. Flanagan +18 more
TL;DR: It is shown that in 37 of 40 individuals with these syndromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of which result in a R132C substitution in the protein.